Exagen Reports Strong Q2 Results: Revenue Up 16%, Net Loss Reduced, Guidance Raised
XGN has more than doubled off its 52-week low of $2.59.
Summary
Exagen Inc. reported record second-quarter revenue, a significant reduction in net loss, and a near-breakeven adjusted EBITDA, leading to an increase in full-year revenue guidance.
Key Events · Earnings and Guidance · XGN
-
Record Revenue Achieved
The company reported record total revenue of $19.9 million for Q2 2026, marking a 16% increase compared to Q2 2025.
-
Net Loss Significantly Reduced
Net loss was reduced by nearly 30% to $(3.196) million in Q2 2026, compared to $(4.439) million in the prior year period.
-
Adjusted EBITDA Nears Breakeven
Adjusted EBITDA loss narrowed significantly to $(0.1) million in Q2 2026, a substantial improvement from a $(1.7) million loss in Q2 2025.
-
Full-Year Guidance Raised
Exagen increased its full-year 2026 revenue guidance to a range of $72 million - $75 million, up from the previous guidance of $70 million - $73 million.
Analysis · XGN · Industrial Applications And Services
Exagen Inc. delivered a strong second quarter, demonstrating significant progress towards profitability. The company achieved record revenue, substantially reduced its net loss, and narrowed its adjusted EBITDA loss to near breakeven. The decision to raise full-year revenue guidance indicates management's increased confidence in continued growth and improved financial performance, which is a positive signal for investors.
At the time of this filing, XGN was trading at $5.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $113.1M. The 52-week trading range was $2.59 to $12.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.